Press release
Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis
Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.
The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.
To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key Market Insights
260 therapy candidates are currently in different phases of development
Nearly 25% of pipeline drugs are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Interestingly, most of these drugs target digestive and gastrointestinal disorders (20%); this is followed by product candidates intended for treatment of oncological disorders (17%) and infectious diseases (13%).
Over 30 microbiome diagnostic tests are currently available / under development
Around 30% of the abovementioned tests have been commercialized, while the rest are under development. Of the total tests, notable examples of companies that launched a microbiome-based diagnostic solution include (in alphabetical order) ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia Scientific and Varinos.
FMTs are the only commercially available microbiome therapy
This therapeutic product is presently indicated for the treatment of recurrent Clostridium difficile infections (rCDIs). Further, non-industry players (such as University of Alberta, The Second Hospital of Nanjing Medical University, University of California and Chinese University of Hong Kong) are making notable contributions in this arena, having been involved in ~200 clinical trials till August 2019.
51% growth in capital investments has been observed since 2015; around 70% investment has come from Venture Capital investors
It is worth noting that more than 80 investors have supported the R&D programs initiated by start-ups focused on microbiome-related products. Well-funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications.
Several big pharma players have microbiome-related initiatives
Leading pharmaceutical companies have actively partnered with smaller business entities to develop capabilities related to microbiome-based therapies / diagnostics. Examples of small ventures that have received support from big pharma players include Assembly Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.
Contract service providers have become an integral part of the microbiome supply chain
Presently, certain firms claim to offer a wide array of contract research / manufacturing services for microbiome therapeutics. Examples of such players include Adare Pharmaceuticals, Biose, Cobra Biologics, CoreBiome, List Biological Laboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.
North America and Europe are anticipated to capture over 85% of the market share by 2030
As late stage products are commercialized, the microbiome therapeutics market is likely to grow at an annualized growth rate of over 30%, during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.
To request a sample copy / brochure of this report, please visit this link
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key Questions Answered
Who are the leading developers of microbiome therapeutics and diagnostic tests?
What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
What are the disease indications against which microbiome-based therapeutics are being evaluated?
Which companies are targeting gut-brain axis for the development of microbiome therapies?
Who are the leading (industry and non-industry) players involved in the development of FMT products?
Who are the key contract research / manufacturing service providers in this domain?
What is the trend in capital investments in microbiome-related R&D?
What are the contributions of big pharma players in this domain?
Which are the popular players offering big data-related services / tools to support microbiome research?
How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?
The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:
Type of Therapy (Tx)
Prescription Drug
Prebiotics
Probiotics
Type of Molecule (Tx)
Small Molecules
Biologics
Target Indication (Tx+Dx)
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Crohn’s Disease
Diabetes
Irritable Bowel Syndrome
Lactose Intolerance
Lung Cancer
Nonalcoholic steatohepatitis (NASH)
Obesity
Ulcerative colitis
Therapeutic Area (Tx+Dx)
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
Key Geographical Regions (Tx+Dx)
North America
Europe
Asia-Pacific and Rest of the World
The report features inputs from eminent industry stakeholders, according to whom innovation in microbiome-related research is mostly being driven by start-ups / small-sized companies. The report includes detailed transcripts of discussions held with the following experts:
Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome)
Lee Jones (President and Chief Executive Officer, Rebiotix)
Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)
Assaf Oron (Chief Business Officer, BiomX)
Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra)
Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics)
James Burges (Executive Director, OpenBiome)
JP Benya (Vice President, Business Development, Assembly Biosciences)
Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
The research covers detailed profiles, featuring a brief company overview, its financial information (if available), product portfolio details (such as status of development of pipeline candidates, clinical trial information and analysis of key trial end-points), recent developments and an informed future outlook.
4D Pharma
Armata Pharmaceuticals
Evelo Biosciences
Rebiotix (Acquired by Ferring Pharmaceuticals)
Seres Therapeutics
Vedanta Biosciences
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
2. Gene Therapy Market (3rd Edition), 2019 - 2030
3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis here
News-ID: 2177160 • Views: …
More Releases from Roots Analysis
T-Cell Therapy Market Size to Hit USD 20.9 billion by 2035| Exclusive Report by …
Cancer is one of the leading causes of mortality across the world. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact,…
Cancer Biologics Market: Unmet Need and Treatment Guidelines
Owing to the increasing mortality rates and growing need for novel modalities to treat oncological disorders, several researchers and industry stakeholders have shifted their focus on the development of safe and effective biologic therapies. Cancer biologics are the class of therapeutic agents, which primarily modulate immune responses or directly inhibits oncogenic pathways in malignancies. These therapies, such as monoclonal antibodies, specifically target tumor-activating genes, facilitate antibody-dependent cellular cytotoxicity and complement…
Peptide Synthesis: Supporting Next Generation Targeted Therapies
Peptides are specialized molecules composed of short chains of amino acids and are used primarily as the active ingredients in a new class of targeted therapeutics. Peptide synthesis is achieved through various advanced methodologies, including chemical processes like solid-phase (SPPS) and liquid-phase (LPPS), as well as hybrid and non-chemical approaches.
Peptides are being extensively used as therapeutics to treat various disorders, including metabolic diseases, oncological disorders, and hormonal imbalances due to…
Prefilled Syringes Market Size to Hit USD 4.97 billion by 2035| Exclusive Report …
Prefilled syringes: setting new standards for safe and efficient drug administration. With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune disorders, cardiovascular disorders and oncological disorders, are witnessing an upward trend.
The global prefilled syringes market, valued at USD 3.02 billion in 2024, is project to reach USD 3.19 billion in 2025 and USD 4.97 billion by 2035, representing a CAGR of 4.5% during the…
More Releases for Mark
MARK WAHLBERG INSTANT EARWORMS!
A jingle for Mark Wahlberg and Wahlburgers ( link below ). Host and enthusiastic Wahlburgers fan DeeDee from CRAZY JOURNEYS with DeeDee is putting out an open invitation to Mark Wahlberg himself - to join her for a fun, fresh photo retake at one of his legendary Wahlburgers locations.
Why? Because every great journey deserves a great snapshot- and the magic of an awesome burger.
DeeDee, whose content on YouTube has…
INTERVIEW: MARK JAMES SCOTT
I sat down with Brand Consultant, Designer & Creative Director Mark James Scott who is making an Impact in the Hip Hop World, in both the UK and the US. We talked working with Artists from The Game and Music Mogul Diddy, to his own Music and more..
BY SASHA JENKINS
WHAT SETS YOU APART FROM OTHERS IN YOUR FIELD?
I didn't study Design. I studied Psychology for 6 years and gained my Masters…
Impressionist landscape artist - Mark Briscoe
I am Mark Briscoe, Bristish artist well established in the field of Chinoiserie furniture decoration and restoration of antique lacquer. But the techniques for fine art easel painting in the wonderful manner of the old masters is something which I have been exploring in great earnest over the last two years as a long cherished desire. And while I cannot claim to have come anywhere near their heights, I have…
Mark de Clive-Lowe
On Thursday, May 3rd, 2012 internationally known musician Mark de Clive-Lowe (MdCL), will take the stage at The Beehive, located in Boston, MA, for a special performance of his revolutionary sound. Be there from 9:30PM to 1:00AM as MdCL plays impromptu remixes created from scratch, on the spot using drum machines, keyboards and special effects. He will start with a jazz-oriented set and crank up the intensity with his signature…
Trade Mark Act
Neoinfo Solutions Pvt. LTD is an IT based company with its main office located in Jaipur(rajasthan). Our expertise lies in the domain of Website Designing development portal development,maintenance software consulting, designing development , implimentation, training and maitenance.In the journey of achieving our combined business and social goals we have kept in mind and have always strictly followed all our data security policies to ensure that all informations of our clients…
Trade mark Act
Neoinfo Solutions Pvt. LTD is an IT based company with its main office located in Jaipur(rajasthan). Our expertise lies in the domain of Website Designing development portal development,maintenance software consulting, designing development , implimentation, training and maitenance.In the journey of achieving our combined business and social goals we have kept in mind and have always strictly followed all our data security policies to ensure that all informations of our clients…
